Marinus Announces Successful Clinical Trial Results and Declares CDKL5 Disorder Its Lead Pediatric Orphan Epilepsy Program for Ganaxolone
Marinus Pharmaceuticals, Inc. (MRNS)
Last marinus pharmaceuticals, inc. earnings: 11/6 07:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.marinuspharma.com/investor-relations
Company Research
Source: GlobeNewswire
Substantial and Durable Anti-Seizure Efficacy Shown in Patients Suffering From Severe, Rare Genetic Epilepsy Marinus to Host Conference Call and Webcast Today at 9:00 am EDT RADNOR, Pa., Sept. 11, 2017 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), today announced that top-line data from the Phase 2 open-label study in patients with CDKL5 disorder support advancing ganaxolone into a definitive late-stage clinical trial. Oral ganaxolone, in addition to baseline treatment, showed a sizable and durable seizure-frequency reduction in the majority of patients, with some achieving an increase in the number of seizure-free days and reporting behavioral benefits. CDKL5 disorder is a severe, rare genetic epilepsy that results in early-onset, treatment-refractory seizures, pervasive neuro-developmental delay and disabling behavioral issues. There are no approved or effective available treatment options. Marinus plans to meet with regulatory agencies to obtain agreement
Show less
Read more
Impact Snapshot
Event Time:
MRNS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MRNS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MRNS alerts
High impacting Marinus Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
MRNS
News
- Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS) had its price target lowered by analysts at Truist Financial Co. from $25.00 to $10.00. They now have a "buy" rating on the stock.MarketBeat
- Lost Money on Marinus Pharmaceuticals, Inc.(MRNS)? Contact Levi & Korsinsky Regarding an Ongoing InvestigationAccesswire
- Marinus (MRNS) Down 83% on Lead Drug Falling Short in Seizure Study [Yahoo! Finance]Yahoo! Finance
- Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $27.00 price target on the stock.MarketBeat
- Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS) was downgraded by analysts at Robert W. Baird from an "outperform" rating to a "neutral" rating. They now have a $2.00 price target on the stock, down previously from $20.00.MarketBeat
MRNS
Earnings
- 3/5/24 - Miss
MRNS
Sec Filings
- 4/4/24 - Form DEFA14A
- 4/4/24 - Form DEF
- 3/27/24 - Form 8-K
- MRNS's page on the SEC website